Indeed, inhibition of sclerostin with romosozumab for treatment of osteoporosis showed increased cardiovascular risk although treated patients were older and take more cardiovascular medication (anticoagulants, antiplatelet agents, antihypertensives) and therefore were probably more likely to have cardiovascular events at baseline [105]. This evidence concerns the gene SOST and osteoporosis.